Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC). Of the 54 eligible patients with measurable or assessable M/AGC, 53 received oxaliplatin 100 mg/m(2) and FA 400 mg/m(2) (2-hou...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 20; číslo 23; s. 4543
Hlavní autori:	Louvet, C, André, T, Tigaud, J M, Gamelin, E, Douillard, J Y, Brunet, R, François, E, Jacob, J H, Levoir, D, Taamma, A, Rougier, P, Cvitkovic, E, de Gramont, A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2002
Predmet:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Drug Administration Schedule Female Fluorouracil - administration & dosage Humans Leucovorin - administration & dosage Male Middle Aged Organoplatinum Compounds - administration & dosage Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Analysis Treatment Outcome
ISSN:	0732-183X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC). Of the 54 eligible patients with measurable or assessable M/AGC, 53 received oxaliplatin 100 mg/m(2) and FA 400 mg/m(2) (2-hour intravenous infusion) followed by 5-FU bolus 400 mg/m(2) (10-minute infusion) and then 5-FU 3,000 mg/m(2) (46-hour continuous infusion) every 14 days. Patients (69% male, 31% female) had a median age of 61 years (range, 31 to 75 years), 89% had a performance status of 0 or 1, 70% had newly diagnosed disease, and 87% had metastatic disease. All had histologically confirmed adenocarcinoma. With a median of three involved organs, disease sites included the lymph nodes (67%), stomach (65%), and liver (61%). A median of 10 cycles per patient and 468 complete cycles were administered. Best responses in the 49 assessable patients were two complete responses and 20 partial responses, giving an overall best response rate of 44.9%. Eight patients underwent complementary treatment with curative intent (six with surgery and two with chemoradiotherapy). Median follow-up, time to progression, and overall survival were 18.6 months, 6.2 months, and 8.6 months, respectively. Grade 3/4 neutropenia, leukopenia, thrombocytopenia, and anemia occurred in 38%, 19%, 4%, and 11% of patients, respectively, and febrile neutropenia occurred in six patients (one episode each). Grade 3 peripheral neuropathy occurred in 21% of patients (oxaliplatin-specific scale). Seven patients withdrew because of treatment-related toxicity. This oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable safety profile in M/AGC patients, and may prove to be a suitable alternative regimen in this indication.
AbstractList	To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC). Of the 54 eligible patients with measurable or assessable M/AGC, 53 received oxaliplatin 100 mg/m(2) and FA 400 mg/m(2) (2-hour intravenous infusion) followed by 5-FU bolus 400 mg/m(2) (10-minute infusion) and then 5-FU 3,000 mg/m(2) (46-hour continuous infusion) every 14 days. Patients (69% male, 31% female) had a median age of 61 years (range, 31 to 75 years), 89% had a performance status of 0 or 1, 70% had newly diagnosed disease, and 87% had metastatic disease. All had histologically confirmed adenocarcinoma. With a median of three involved organs, disease sites included the lymph nodes (67%), stomach (65%), and liver (61%). A median of 10 cycles per patient and 468 complete cycles were administered. Best responses in the 49 assessable patients were two complete responses and 20 partial responses, giving an overall best response rate of 44.9%. Eight patients underwent complementary treatment with curative intent (six with surgery and two with chemoradiotherapy). Median follow-up, time to progression, and overall survival were 18.6 months, 6.2 months, and 8.6 months, respectively. Grade 3/4 neutropenia, leukopenia, thrombocytopenia, and anemia occurred in 38%, 19%, 4%, and 11% of patients, respectively, and febrile neutropenia occurred in six patients (one episode each). Grade 3 peripheral neuropathy occurred in 21% of patients (oxaliplatin-specific scale). Seven patients withdrew because of treatment-related toxicity. This oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable safety profile in M/AGC patients, and may prove to be a suitable alternative regimen in this indication. To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC).PURPOSETo evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric cancer (M/AGC).Of the 54 eligible patients with measurable or assessable M/AGC, 53 received oxaliplatin 100 mg/m(2) and FA 400 mg/m(2) (2-hour intravenous infusion) followed by 5-FU bolus 400 mg/m(2) (10-minute infusion) and then 5-FU 3,000 mg/m(2) (46-hour continuous infusion) every 14 days.PATIENTS AND METHODSOf the 54 eligible patients with measurable or assessable M/AGC, 53 received oxaliplatin 100 mg/m(2) and FA 400 mg/m(2) (2-hour intravenous infusion) followed by 5-FU bolus 400 mg/m(2) (10-minute infusion) and then 5-FU 3,000 mg/m(2) (46-hour continuous infusion) every 14 days.Patients (69% male, 31% female) had a median age of 61 years (range, 31 to 75 years), 89% had a performance status of 0 or 1, 70% had newly diagnosed disease, and 87% had metastatic disease. All had histologically confirmed adenocarcinoma. With a median of three involved organs, disease sites included the lymph nodes (67%), stomach (65%), and liver (61%). A median of 10 cycles per patient and 468 complete cycles were administered. Best responses in the 49 assessable patients were two complete responses and 20 partial responses, giving an overall best response rate of 44.9%. Eight patients underwent complementary treatment with curative intent (six with surgery and two with chemoradiotherapy). Median follow-up, time to progression, and overall survival were 18.6 months, 6.2 months, and 8.6 months, respectively. Grade 3/4 neutropenia, leukopenia, thrombocytopenia, and anemia occurred in 38%, 19%, 4%, and 11% of patients, respectively, and febrile neutropenia occurred in six patients (one episode each). Grade 3 peripheral neuropathy occurred in 21% of patients (oxaliplatin-specific scale). Seven patients withdrew because of treatment-related toxicity.RESULTSPatients (69% male, 31% female) had a median age of 61 years (range, 31 to 75 years), 89% had a performance status of 0 or 1, 70% had newly diagnosed disease, and 87% had metastatic disease. All had histologically confirmed adenocarcinoma. With a median of three involved organs, disease sites included the lymph nodes (67%), stomach (65%), and liver (61%). A median of 10 cycles per patient and 468 complete cycles were administered. Best responses in the 49 assessable patients were two complete responses and 20 partial responses, giving an overall best response rate of 44.9%. Eight patients underwent complementary treatment with curative intent (six with surgery and two with chemoradiotherapy). Median follow-up, time to progression, and overall survival were 18.6 months, 6.2 months, and 8.6 months, respectively. Grade 3/4 neutropenia, leukopenia, thrombocytopenia, and anemia occurred in 38%, 19%, 4%, and 11% of patients, respectively, and febrile neutropenia occurred in six patients (one episode each). Grade 3 peripheral neuropathy occurred in 21% of patients (oxaliplatin-specific scale). Seven patients withdrew because of treatment-related toxicity.This oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable safety profile in M/AGC patients, and may prove to be a suitable alternative regimen in this indication.CONCLUSIONThis oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable safety profile in M/AGC patients, and may prove to be a suitable alternative regimen in this indication.
Author	Taamma, A Cvitkovic, E Louvet, C Douillard, J Y François, E Gamelin, E de Gramont, A Jacob, J H Levoir, D Tigaud, J M Brunet, R Rougier, P André, T
Author_xml	– sequence: 1 givenname: C surname: Louvet fullname: Louvet, C email: christophe.louvet@sat.ap-hop-paris.fr organization: Service d' Oncologie-Médecine Interne, Hôpital Saint-Antoine, Paris, France. christophe.louvet@sat.ap-hop-paris.fr – sequence: 2 givenname: T surname: André fullname: André, T – sequence: 3 givenname: J M surname: Tigaud fullname: Tigaud, J M – sequence: 4 givenname: E surname: Gamelin fullname: Gamelin, E – sequence: 5 givenname: J Y surname: Douillard fullname: Douillard, J Y – sequence: 6 givenname: R surname: Brunet fullname: Brunet, R – sequence: 7 givenname: E surname: François fullname: François, E – sequence: 8 givenname: J H surname: Jacob fullname: Jacob, J H – sequence: 9 givenname: D surname: Levoir fullname: Levoir, D – sequence: 10 givenname: A surname: Taamma fullname: Taamma, A – sequence: 11 givenname: P surname: Rougier fullname: Rougier, P – sequence: 12 givenname: E surname: Cvitkovic fullname: Cvitkovic, E – sequence: 13 givenname: A surname: de Gramont fullname: de Gramont, A
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/12454110$$D View this record in MEDLINE/PubMed
BookMark	eNo1kL1PwzAUxD0U0VKY2ZAnpqb4OU6cjKjio1IlGEBii1x_gCvHDnYC9L8nQJFO-p3unW54J2jig9cInQNZAiXkaifDciRd_gomaEZ4TjOo8pcpOklpRwiwKi-O0RQoKxgAmaHPxzeRNF6vceoHtcfB4PAlnO2c6K1fYOOGEMMQhbRugYVX2ARnvZV4TBS2HrsghXN7LNSH8FIrHCJudS9SPy5I_DqaOFL-HCPuxlD7Pp2iIyNc0mcHztHz7c3T6j7bPNytV9ebTDIKfbaljHPBeG44V3UFtARpQFZbXmtW5DmjCgwUygilgJe6rIVRpNKVgIJxZegcXf7tdjG8Dzr1TWuT1M4Jr8OQGk451GVZjcWLQ3HYtlo1XbStiPvm_1X0G8bQbLM
CitedBy_id	crossref_primary_10_1016_j_ejcsup_2004_04_014 crossref_primary_10_1038_sj_bjc_6604188 crossref_primary_10_1158_1078_0432_CCR_05_2425 crossref_primary_10_1186_1744_8069_7_29 crossref_primary_10_1200_JCO_2005_11_593 crossref_primary_10_1093_annonc_mdr284 crossref_primary_10_1007_s10120_007_0415_x crossref_primary_10_1038_bjc_2012_555 crossref_primary_10_1097_COC_0b013e318042d582 crossref_primary_10_1007_s11912_006_0018_4 crossref_primary_10_1038_sj_bjc_6601752 crossref_primary_10_1186_1471_2407_8_148 crossref_primary_10_1093_annonc_mdn403 crossref_primary_10_1093_annonc_mdn766 crossref_primary_10_1007_s00280_009_1013_x crossref_primary_10_1016_j_ejca_2007_11_001 crossref_primary_10_1007_s10120_011_0128_z crossref_primary_10_1634_theoncologist_10_90003_49 crossref_primary_10_1016_j_ejphar_2024_176818 crossref_primary_10_1016_j_jpba_2008_10_028 crossref_primary_10_1179_joc_2011_23_1_28 crossref_primary_10_1016_j_ctrv_2012_09_007 crossref_primary_10_1007_s00280_008_0797_4 crossref_primary_10_1097_MAJ_0b013e3181c4bd91 crossref_primary_10_1179_1973947813Y_0000000133 crossref_primary_10_1097_CAD_0b013e3280146296 crossref_primary_10_1002_jssc_202400164 crossref_primary_10_1007_s00761_005_0910_9 crossref_primary_10_1016_j_ejso_2011_01_027 crossref_primary_10_1634_theoncologist_9_3_282 crossref_primary_10_1016_j_pain_2009_09_003 crossref_primary_10_1097_01_cad_0000198912_98442_cd crossref_primary_10_1038_sj_bjc_6601985 crossref_primary_10_1093_annonc_mdh422 crossref_primary_10_1053_j_seminoncol_2004_11_006 crossref_primary_10_1093_annonc_mdg453 crossref_primary_10_1186_1471_2407_6_125 crossref_primary_10_1186_1749_8546_5_25 crossref_primary_10_1517_14656566_5_10_2109 crossref_primary_10_1097_CAD_0000000000001143 crossref_primary_10_1188_03_CJON_353_356 crossref_primary_10_1016_j_oraloncology_2005_11_001 crossref_primary_10_1016_j_emcchi_2003_10_003 crossref_primary_10_1007_s10120_011_0007_7 crossref_primary_10_3892_ijmm_2014_1664 crossref_primary_10_1007_s10120_012_0204_z crossref_primary_10_1186_1744_8069_5_9 crossref_primary_10_1080_02841860600949578 crossref_primary_10_3892_mco_2015_592 crossref_primary_10_3892_ol_2012_1096 crossref_primary_10_1016_j_neuro_2006_04_010 crossref_primary_10_1007_s00280_013_2334_3 crossref_primary_10_1093_annonc_mdh473 crossref_primary_10_1016_S1548_5315_11_70945_7 crossref_primary_10_1159_000457791 crossref_primary_10_1097_CAD_0b013e3282f3fd17 crossref_primary_10_1093_annonc_mdi281 crossref_primary_10_4240_wjgs_v17_i4_100800 crossref_primary_10_1159_000366425 crossref_primary_10_1002_rcm_2622 crossref_primary_10_1038_sj_bjc_6602572 crossref_primary_10_1038_sj_bjc_6602573 crossref_primary_10_1097_01_coc_0000162424_69631_79 crossref_primary_10_1007_s10620_010_1280_8 crossref_primary_10_1007_s00280_005_1024_1 crossref_primary_10_1097_MD_0000000000021770 crossref_primary_10_1007_s44178_022_00004_x crossref_primary_10_1177_030089160909500108 crossref_primary_10_1038_sj_bjc_6602697 crossref_primary_10_1093_annonc_mdm128 crossref_primary_10_1093_jjco_hys084 crossref_primary_10_1097_01_mog_0000179833_28158_b7 crossref_primary_10_1093_annonc_mdl317 crossref_primary_10_1097_01_coc_0000221358_57089_f2 crossref_primary_10_1111_j_1349_7006_2006_00253_x crossref_primary_10_1179_joc_2005_17_6_656 crossref_primary_10_1016_S1359_6349_06_70003_9 crossref_primary_10_1097_MD_0000000000002106 crossref_primary_10_1007_s00280_009_0938_4 crossref_primary_10_1007_s10637_011_9726_1 crossref_primary_10_1007_s00761_008_1458_2 crossref_primary_10_1093_jjco_hyn119 crossref_primary_10_1016_j_critrevonc_2005_01_002 crossref_primary_10_1007_s00280_010_1281_5 crossref_primary_10_1016_j_biopha_2008_08_018 crossref_primary_10_1016_j_ejca_2010_10_013 crossref_primary_10_3748_wjg_14_2323 crossref_primary_10_3892_ol_2011_496 crossref_primary_10_1016_j_critrevonc_2009_01_004 crossref_primary_10_1016_j_ejca_2013_04_022 crossref_primary_10_1007_s00432_008_0376_4 crossref_primary_10_1007_s00761_004_0785_1 crossref_primary_10_1093_annonc_mdq435 crossref_primary_10_3389_fimmu_2023_1237764 crossref_primary_10_1159_000097768 crossref_primary_10_1038_bjc_2016_126 crossref_primary_10_2217_pgs_13_88 crossref_primary_10_1002_jssc_200700418 crossref_primary_10_1007_s00280_008_0753_3 crossref_primary_10_1007_s12668_024_01651_2 crossref_primary_10_1016_S1470_2045_08_70042_1 crossref_primary_10_1080_07357900600705268 crossref_primary_10_2147_CMAR_S278902 crossref_primary_10_1097_CAD_0b013e3283273509 crossref_primary_10_1200_JCO_2004_07_042 crossref_primary_10_1093_annonc_mdh909 crossref_primary_10_7475_kjan_2016_28_3_343 crossref_primary_10_1016_j_ejso_2013_05_003 crossref_primary_10_1038_sj_bjc_6603046 crossref_primary_10_1136_jitc_2023_007927 crossref_primary_10_1016_j_clon_2004_12_004 crossref_primary_10_1080_17512433_2017_1279969 crossref_primary_10_1053_j_seminoncol_2005_12_010 crossref_primary_10_1097_CAD_0b013e328324bbc1 crossref_primary_10_1007_s12032_010_9741_7 crossref_primary_10_1200_JCO_2007_13_9378 crossref_primary_10_2217_14796694_2_5_603 crossref_primary_10_1200_JCO_2004_01_140 crossref_primary_10_1016_j_clinre_2011_08_002 crossref_primary_10_1001_jamanetworkopen_2022_0426 crossref_primary_10_1177_030089160709300303 crossref_primary_10_1080_07357907_2017_1337782 crossref_primary_10_1097_01_coc_0000235997_18657_a6 crossref_primary_10_1179_joc_2010_22_5_298 crossref_primary_10_1080_07357900500202713 crossref_primary_10_1016_j_jgo_2015_06_002 crossref_primary_10_1097_00001813_200307000_00006 crossref_primary_10_1097_COC_0b013e3181f47ac1 crossref_primary_10_1007_s00280_012_1956_1 crossref_primary_10_1007_s00384_012_1434_6 crossref_primary_10_1016_j_bulcan_2014_08_001 crossref_primary_10_3892_mmr_2013_1435 crossref_primary_10_1093_annonc_mdi249 crossref_primary_10_1007_s10038_005_0339_4 crossref_primary_10_1038_sj_bjc_6603752 crossref_primary_10_1093_annonc_mdh312 crossref_primary_10_1038_sj_bjc_6603917 crossref_primary_10_1007_s00280_008_0752_4 crossref_primary_10_1097_SPC_0000000000000515 crossref_primary_10_1080_07357900701358025 crossref_primary_10_1097_j_pain_0000000000001212 crossref_primary_10_1200_JCO_2005_06_023 crossref_primary_10_1016_j_expneurol_2011_02_019 crossref_primary_10_1097_COC_0000000000000271 crossref_primary_10_3390_cancers13235929 crossref_primary_10_1111_ajco_12833 crossref_primary_10_1007_s10120_005_0342_7 crossref_primary_10_1186_1756_9966_28_34 crossref_primary_10_1155_2016_6857625 crossref_primary_10_1016_j_ctrv_2007_01_004 crossref_primary_10_1177_1758834010365061 crossref_primary_10_1016_j_critrevonc_2008_08_005 crossref_primary_10_1038_sj_bjc_6604317 crossref_primary_10_1007_s00280_007_0454_3 crossref_primary_10_1093_annonc_mdn013 crossref_primary_10_1016_j_ejca_2019_04_020 crossref_primary_10_1200_JCO_2015_65_5092 crossref_primary_10_3389_fphar_2016_00414 crossref_primary_10_1007_s12032_012_0451_1 crossref_primary_10_1038_sj_bjc_6603225 crossref_primary_10_1093_annonc_mdm449 crossref_primary_10_1039_C7TX00345E crossref_primary_10_1200_JCO_2006_08_0135 crossref_primary_10_1016_j_biomaterials_2013_06_004 crossref_primary_10_1093_annonc_mdi252 crossref_primary_10_1179_joc_2008_20_6_744 crossref_primary_10_1080_02841860600791483 crossref_primary_10_1038_sj_bjc_6605928 crossref_primary_10_3109_07357901003630942 crossref_primary_10_1002_jso_23009 crossref_primary_10_1007_s00280_009_0936_6 crossref_primary_10_1007_s10120_013_0297_z crossref_primary_10_1007_s11605_011_1623_6 crossref_primary_10_1080_02841860701253060 crossref_primary_10_3389_fonc_2020_584772
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1200/jco.2002.02.021
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID	12454110
Genre	Multicenter Study Clinical Trial, Phase II Clinical Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- .55 .GJ 08G 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 8WZ A6W AAKAS AARDX AAWTL AAYEP ABJNI ABOCM ACGFO ACGFS ADZCM AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN C45 CGR CS3 CUY CVF DIK ECM EIF EJD EX3 F5P F9R FBNNL FD8 FEDTE H13 HVGLF HZ~ IH2 KQ8 L7B MJL N4W N9A NPM NTWIH O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS UHU VH1 VVN WH7 WOQ WOW X7M YCJ YFH YQY ZGI 7X8 ABBLC
ID	FETCH-LOGICAL-c421t-b2477a473f77d981261cf1c8b79e453342d1f15dfadd176e69afd08e8a1547df2
IEDL.DBID	7X8
ISICitedReferencesCount	253
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000179632200006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0732-183X
IngestDate	Thu Oct 02 12:10:08 EDT 2025 Sat Sep 28 07:53:18 EDT 2024
IsPeerReviewed	true
IsScholarly	true
Issue	23
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c421t-b2477a473f77d981261cf1c8b79e453342d1f15dfadd176e69afd08e8a1547df2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	12454110
PQID	72719668
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_72719668 pubmed_primary_12454110
PublicationCentury	2000
PublicationDate	2002-12-01
PublicationDateYYYYMMDD	2002-12-01
PublicationDate_xml	– month: 12 year: 2002 text: 2002-12-01 day: 01
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of clinical oncology
PublicationTitleAlternate	J Clin Oncol
PublicationYear	2002
SSID	ssj0014835
Score	2.2473693
Snippet	To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FA) combination in patients with metastatic or advanced gastric...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	4543
SubjectTerms	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Drug Administration Schedule Female Fluorouracil - administration & dosage Humans Leucovorin - administration & dosage Male Middle Aged Organoplatinum Compounds - administration & dosage Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Analysis Treatment Outcome
Title	Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients
URI	https://www.ncbi.nlm.nih.gov/pubmed/12454110 https://www.proquest.com/docview/72719668
Volume	20
WOSCitedRecordID	wos000179632200006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB6SJoRe2jz6SNMmcwg5WUSS19oVFEIJDUkgjg8J-GZWuzvB4Equ5bT1v-_sSsKn0EMvAr3F7szOh2bm-wBOB1aQ0kSRtsUgEsSerjnqRsKk5Fzu-hTbIDYhh0M1HuejDfja9cL4sspuTQwLta2M_0d-znGWjSVTF_OfkdeM8rnVVkBjE7b6DGS8TcvxOocgVCOvKftpxIY7bol92CzOby_vQ3VCoOtMk5fRZYgyV2__7_t24U2LLvFbYw57sOHKfdi5a_Pn-3A2apiqVz18WDde1T08w9Gaw3p1AL95t3Z4c4OBfxYrwuoPQ_a5L50re0iz52rBb9NmOuuhLi1SFXoskY9YnJYYguRshV2RAVYL_OGW2ncw8WVP2guGGDT-5AJbetf6HTxefX-4vI5ajYbIiDRZRkUqpNRC9klKmzNayBJDiVGFzJ3wbb6pTSgZWOJ1NJGZy3JNNlZOacZu0lL6Hl6VVek-AmrGErGjzOQkRSaKQumYn5Qpp3ly4_gQTrqRn7AP-MSGLl31XE-6sT-ED83kTeYNVceE0ctAMML59M97j-B1J_QSJ59hi9j73RfYNr-W03pxHEyLt8PR3V_xB9sX
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+II+study+of+oxaliplatin%2C+fluorouracil%2C+and+folinic+acid+in+locally+advanced+or+metastatic+gastric+cancer+patients&rft.jtitle=Journal+of+clinical+oncology&rft.au=Louvet%2C+C&rft.au=Andr%C3%A9%2C+T&rft.au=Tigaud%2C+J+M&rft.au=Gamelin%2C+E&rft.date=2002-12-01&rft.issn=0732-183X&rft.volume=20&rft.issue=23&rft.spage=4543&rft_id=info:doi/10.1200%2Fjco.2002.02.021&rft_id=info%3Apmid%2F12454110&rft_id=info%3Apmid%2F12454110&rft.externalDocID=12454110
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon